ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

被引：0
|
作者：
J Wei
Z Zou
X Qian
Y Ding
L Xie
J J Sanchez
Y Zhao
J Feng
Y Ling
Y Liu
L Yu
R Rosell
B Liu
机构：
[1] Drum Tower Hospital,Department of Oncology
[2] Clinical Cancer Institute of Nanjing University,Department of Preventive Medicine and Public Health
[3] Medical School of Nanjing University,Department of Epidemiology and Biostatistics and Data Analysis Center
[4] Medical Oncology Service,Department of Oncology
[5] Catalan Institute of Oncology,Department of Oncology
[6] Hospital Germans Trias i Pujol,undefined
[7] Autonomous University of Madrid,undefined
[8] School of Public Health,undefined
[9] Nanjing Medical University,undefined
[10] Jiangsu Cancer Hospital,undefined
[11] Changzhou Cancer Hospital,undefined
[12] Suzhou University,undefined
来源：
British Journal of Cancer | 2008年 / 98卷
关键词：
advanced gastric cancer; FOLFOX;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum chemotherapy. Excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were assessed in advanced gastric cancer tumour samples using real-time quantitative PCR in 76 patients treated with a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen. Median survival time in patients with low ERCC1 levels was significantly longer than in those with high levels (15.8 vs 6.2 months; P<0.0001). Patients with high TS levels had longer survival than those with low levels (12.2 vs 10.1 months; P=0.01). Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1 months (P<0.0001). The hazard ratio for patients with high ERCC1 expression was 9.4 (P<0.0001). In patients with high mRNA levels of ERCC1, alternative chemotherapy regimens should be considered.
引用
收藏
页码：1398 / 1402
页数：4
相关论文
共 50 条
  • [1] ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
    Wei, J.
    Zou, Z.
    Qian, X.
    Ding, Y.
    Xie, L.
    Sanchez, J. J.
    Zhao, Y.
    Feng, J.
    Ling, Y.
    Liu, Y.
    Yu, L.
    Rosell, R.
    Liu, B.
    BRITISH JOURNAL OF CANCER, 2008, 98 (08) : 1398 - 1402
  • [2] ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
    Li, Yangkai
    Liu, Zhensheng
    Liu, Hongliang
    Wang, Li-E
    Tan, Dongfeng
    Ajani, Jaffer A.
    Wei, Qing-Yi
    PLOS ONE, 2013, 8 (09):
  • [3] SIGNIFICANCE OF TWO ERCC1 POLYMORPHISMS AND PRETHERAPEUTIC ERCC1 MRNA LEVELS IN COLORECTAL CANCER
    Kaskara, A. V.
    Antonacopoulou, A.
    Rigopoulos, A. G.
    Mavroudis, D.
    Scopa, C.
    Georgoulias, V.
    Kalofonos, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 137 - 138
  • [4] ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy
    Metzger, R
    Leichman, CG
    Danenberg, KD
    Danenberg, PV
    Lenz, HJ
    Hayashi, K
    Groshen, S
    Salonga, D
    Cohen, H
    Laine, L
    Crookes, P
    Silberman, H
    Baranda, J
    Konda, K
    Leichman, L
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 309 - 316
  • [5] Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
    Lu, Zheng-mao
    Luo, Tian-hang
    Nie, Ming-ming
    Fang, Guo-en
    Ma, Li-ye
    Xue, Xu-chao
    Wei, Guo
    Ke, Chong-we
    Bi, Jian-wei
    TUMOR BIOLOGY, 2014, 35 (04) : 2941 - 2948
  • [6] Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC)
    Guancial, Elizabeth A.
    Werner, Lillian
    Bellmunt, Joaquim
    Nikitas, Nikitas
    Stack, Edward C.
    Lis, Rosina
    Signoretti, Sabina
    Loda, Massimo
    Regan, Meredith M.
    Park, Rachel S.
    O'Brien, Robert
    Berman, David M.
    Bamias, Aristotelis
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [7] The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Liu, Yong-Ping
    Ling, Yang
    Qi, Qiu-Feng
    Zhang, Ya-Ping
    Zhang, Chang-Song
    Zhu, Chang-Tai
    Wang, Mei-Hua
    Pan, Yao-Dong
    ONCOLOGY LETTERS, 2013, 5 (03) : 935 - 942
  • [8] A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients
    Woelfelschneider, Andreas
    Popanda, Odilia
    Lilla, Carmen
    Linseisen, Jakob
    Mayer, Claudia
    Celebi, Oktay
    Debus, Juergen
    Bartsch, Helmut
    Chang-Claude, Jenny
    Schmezer, Peter
    CARCINOGENESIS, 2008, 29 (09) : 1758 - 1764
  • [9] Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone
    Doll, Corinne M.
    Prystajecky, Michael
    Eliasziw, Misha
    Klimowicz, Alexander C.
    Petrillo, Stephanie K.
    Craighead, Peter S.
    Hao, Desiree
    Diaz, Roman
    Lees-Miller, Susan P.
    Magliocco, Anthony M.
    RADIOTHERAPY AND ONCOLOGY, 2010, 97 (02) : 352 - 359
  • [10] ERCC1 expression can predict survival in patients with advanced head and neck cancer
    Nature Clinical Practice Oncology, 2007, 4 (10): : 559 - 559
12345